An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes
P-SP420-THAL-01
Phase 2 other active
Quick answer
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes for transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes is a Phase 2 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes
- Phase
- Phase 2
- Modality
- other
- Status
- active